PortalPublikationenImmuntherapie beim Aderhautmelanom: Vakzination gegen Krebs:...

Immuntherapie beim Aderhautmelanom: Vakzination gegen Krebs: Multizentrische adjuvante Phase-III-Impfstudie mit Tumor-RNA-beladenen dendritischen Zellen bei neu diagnostizierten, großen Uveamelanomen

Standard

Immuntherapie beim Aderhautmelanom: Vakzination gegen Krebs: Multizentrische adjuvante Phase-III-Impfstudie mit Tumor-RNA-beladenen dendritischen Zellen bei neu diagnostizierten, großen Uveamelanomen. / Schuler-Thurner, B; Bartz-Schmidt, K-U; Bornfeld, N; Cursiefen, C; Fuisting, B; Grisanti, S; Heindl, L M; Holbach, L; Keserü, M; Knorr, H; Koch, K; Kruse, F; Meiller, R; Metz, C; Meyer-Ter-Vehn, T; Much, M; Reinsberg, M; Schliep, S; Seitz, B; Schuler, G; Süsskind, D; Viestenz, A; Wagenfeld, L; Zeschnigk, M.

in: OPHTHALMOLOGE, Jahrgang 112, Nr. 12, 24.11.2015, S. 1017-1021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schuler-Thurner, B, Bartz-Schmidt, K-U, Bornfeld, N, Cursiefen, C, Fuisting, B, Grisanti, S, Heindl, LM, Holbach, L, Keserü, M, Knorr, H, Koch, K, Kruse, F, Meiller, R, Metz, C, Meyer-Ter-Vehn, T, Much, M, Reinsberg, M, Schliep, S, Seitz, B, Schuler, G, Süsskind, D, Viestenz, A, Wagenfeld, L & Zeschnigk, M 2015, 'Immuntherapie beim Aderhautmelanom: Vakzination gegen Krebs: Multizentrische adjuvante Phase-III-Impfstudie mit Tumor-RNA-beladenen dendritischen Zellen bei neu diagnostizierten, großen Uveamelanomen', OPHTHALMOLOGE, Jg. 112, Nr. 12, S. 1017-1021. https://doi.org/10.1007/s00347-015-0162-z

APA

Schuler-Thurner, B., Bartz-Schmidt, K-U., Bornfeld, N., Cursiefen, C., Fuisting, B., Grisanti, S., Heindl, L. M., Holbach, L., Keserü, M., Knorr, H., Koch, K., Kruse, F., Meiller, R., Metz, C., Meyer-Ter-Vehn, T., Much, M., Reinsberg, M., Schliep, S., Seitz, B., ... Zeschnigk, M. (2015). Immuntherapie beim Aderhautmelanom: Vakzination gegen Krebs: Multizentrische adjuvante Phase-III-Impfstudie mit Tumor-RNA-beladenen dendritischen Zellen bei neu diagnostizierten, großen Uveamelanomen. OPHTHALMOLOGE, 112(12), 1017-1021. https://doi.org/10.1007/s00347-015-0162-z

Vancouver

Schuler-Thurner B, Bartz-Schmidt K-U, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S et al. Immuntherapie beim Aderhautmelanom: Vakzination gegen Krebs: Multizentrische adjuvante Phase-III-Impfstudie mit Tumor-RNA-beladenen dendritischen Zellen bei neu diagnostizierten, großen Uveamelanomen. OPHTHALMOLOGE. 2015 Nov 24;112(12):1017-1021. https://doi.org/10.1007/s00347-015-0162-z

Bibtex

@article{3b52fef557d64e8fbe6e830fafe1776d,
title = "Immuntherapie beim Aderhautmelanom: Vakzination gegen Krebs: Multizentrische adjuvante Phase-III-Impfstudie mit Tumor-RNA-beladenen dendritischen Zellen bei neu diagnostizierten, gro{\ss}en Uveamelanomen",
abstract = "Uveal melanomas are the most common malignant tumors of the eye. With modern molecular biological diagnostic methods, such as chromosome 3 typing and gene expression analysis, these tumors can be categorized into highly aggressive (monosomy 3, class II) and less aggressive forms. This molecular biological stratification is primarily important for determining the risk of these tumors as no therapy is currently available that is able to prevent or delay metastases. A randomized study of patients with a poor prognosis (monosomy 3) is currently being carried out in order to determine whether a cancer vaccine prepared from autologous (patient's own) dendritic cells and uveal melanoma RNA can prevent or delay progression and further metastases of this extremely aggressive form of cancer. Inclusion in the uveal melanoma study, which hopes to provide a potential therapeutic option for patients, is only possible if patients are referred to an institution that is able to manufacture and provide this vaccination before the patient is operated on or treated with radiation. Untreated tumor material is necessary for producing the vaccine on an individualized patient basis.",
author = "B Schuler-Thurner and K-U Bartz-Schmidt and N Bornfeld and C Cursiefen and B Fuisting and S Grisanti and Heindl, {L M} and L Holbach and M Keser{\"u} and H Knorr and K Koch and F Kruse and R Meiller and C Metz and T Meyer-Ter-Vehn and M Much and M Reinsberg and S Schliep and B Seitz and G Schuler and D S{\"u}sskind and A Viestenz and L Wagenfeld and M Zeschnigk",
year = "2015",
month = nov,
day = "24",
doi = "10.1007/s00347-015-0162-z",
language = "Deutsch",
volume = "112",
pages = "1017--1021",
journal = "OPHTHALMOLOGE",
issn = "0941-293X",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Immuntherapie beim Aderhautmelanom: Vakzination gegen Krebs: Multizentrische adjuvante Phase-III-Impfstudie mit Tumor-RNA-beladenen dendritischen Zellen bei neu diagnostizierten, großen Uveamelanomen

AU - Schuler-Thurner, B

AU - Bartz-Schmidt, K-U

AU - Bornfeld, N

AU - Cursiefen, C

AU - Fuisting, B

AU - Grisanti, S

AU - Heindl, L M

AU - Holbach, L

AU - Keserü, M

AU - Knorr, H

AU - Koch, K

AU - Kruse, F

AU - Meiller, R

AU - Metz, C

AU - Meyer-Ter-Vehn, T

AU - Much, M

AU - Reinsberg, M

AU - Schliep, S

AU - Seitz, B

AU - Schuler, G

AU - Süsskind, D

AU - Viestenz, A

AU - Wagenfeld, L

AU - Zeschnigk, M

PY - 2015/11/24

Y1 - 2015/11/24

N2 - Uveal melanomas are the most common malignant tumors of the eye. With modern molecular biological diagnostic methods, such as chromosome 3 typing and gene expression analysis, these tumors can be categorized into highly aggressive (monosomy 3, class II) and less aggressive forms. This molecular biological stratification is primarily important for determining the risk of these tumors as no therapy is currently available that is able to prevent or delay metastases. A randomized study of patients with a poor prognosis (monosomy 3) is currently being carried out in order to determine whether a cancer vaccine prepared from autologous (patient's own) dendritic cells and uveal melanoma RNA can prevent or delay progression and further metastases of this extremely aggressive form of cancer. Inclusion in the uveal melanoma study, which hopes to provide a potential therapeutic option for patients, is only possible if patients are referred to an institution that is able to manufacture and provide this vaccination before the patient is operated on or treated with radiation. Untreated tumor material is necessary for producing the vaccine on an individualized patient basis.

AB - Uveal melanomas are the most common malignant tumors of the eye. With modern molecular biological diagnostic methods, such as chromosome 3 typing and gene expression analysis, these tumors can be categorized into highly aggressive (monosomy 3, class II) and less aggressive forms. This molecular biological stratification is primarily important for determining the risk of these tumors as no therapy is currently available that is able to prevent or delay metastases. A randomized study of patients with a poor prognosis (monosomy 3) is currently being carried out in order to determine whether a cancer vaccine prepared from autologous (patient's own) dendritic cells and uveal melanoma RNA can prevent or delay progression and further metastases of this extremely aggressive form of cancer. Inclusion in the uveal melanoma study, which hopes to provide a potential therapeutic option for patients, is only possible if patients are referred to an institution that is able to manufacture and provide this vaccination before the patient is operated on or treated with radiation. Untreated tumor material is necessary for producing the vaccine on an individualized patient basis.

U2 - 10.1007/s00347-015-0162-z

DO - 10.1007/s00347-015-0162-z

M3 - SCORING: Zeitschriftenaufsatz

C2 - 26602097

VL - 112

SP - 1017

EP - 1021

JO - OPHTHALMOLOGE

JF - OPHTHALMOLOGE

SN - 0941-293X

IS - 12

ER -